Board and Committee Changes

RNS Number : 8440X

GlaxoSmithKline PLC

06 May 2021

 

GlaxoSmithKline plc

GSK announces changes to its Board and Committees

GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.

As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee.

In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee. 

Note

1.	From 6 May 2021 the Board of GSK comprises
	Sir Jonathan Symonds  Emma Walmsley    Iain Mackay    Dr Hal Barron   Vindi Banga   Charles Bancroft Dr Anne Beal Dr Vivienne Cox    Lynn Elsenhans  Dr Jesse Goodman    Dr Laurie Glimcher    Urs Rohner	Non-Executive Chairman Chief Executive Officer Chief Financial Officer Chief Scientific Officer and President, R&D Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director

V A Whyte

Company Secretary

6 May 2021

 

END

 

 

BOABLGDUCSGDGBL